
Virtual Cell Models Move From Contest to Drug Discovery: What Illumina's Win Shows
Dr. Dereck Mush, MD, MBADNA sequencing and array-based technologies for research, clinical and applied markets.
Illumina is a San Diego genomics company focused on DNA sequencing and array-based technologies for research, clinical and applied markets. It trades on NASDAQ under ILMN. Rami Mehio is senior vice president and general manager of its BioInsight business. Kyle Farh, MD, PhD, vice president of artificial intelligence, runs the BioInsight AI Lab.
How Illumina got here, step by step.
19 November 2026
Announced that its BioInsight AI Lab won the 2026 Virtual Cell Challenge, hosted by Arc Institute, among roughly 1,500 competitors. Its new CellularAI algorithm was trained on the Illumina Billion Cell Atlas, a genome-wide CRISPR perturbation dataset across more than 200 disease-relevant cell lines generated in a consortium with select pharmaceutical partners. An open-source initial version of CellularAI was released the same day.
19 November 2026
Virtual Cell Challenge win
Dr. Dereck Mush, MD, MBAMentions Illumina

Dr. Dereck Mush, MD, MBAMentions Illumina

Dr. Dereck Mush, MD, MBAMentions Illumina
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: